000136819 001__ 136819
000136819 005__ 20240229105101.0
000136819 0247_ $$2doi$$a10.1007/s10549-018-4754-6
000136819 0247_ $$2pmid$$apmid:29556781
000136819 0247_ $$2ISSN$$a0167-6806
000136819 0247_ $$2ISSN$$a1573-7217
000136819 0247_ $$2altmetric$$aaltmetric:34662687
000136819 037__ $$aDKFZ-2018-01257
000136819 041__ $$aeng
000136819 082__ $$a610
000136819 1001_ $$00000-0002-3114-8273$$aThöne, Kathrin$$b0
000136819 245__ $$aPrognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis.
000136819 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2018
000136819 3367_ $$2DRIVER$$aarticle
000136819 3367_ $$2DataCite$$aOutput Types/Journal article
000136819 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536239132_3592
000136819 3367_ $$2BibTeX$$aARTICLE
000136819 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136819 3367_ $$00$$2EndNote$$aJournal Article
000136819 520__ $$aRecent cohort studies demonstrated better overall survival (OS) or breast cancer-specific survival (BCS) for breast-conserving therapy (BCT) followed by radiation (RT) compared to mastectomy alone (MT). This is the first observational study in which adjustments for a comprehensive set of prognostic factors, adjuvant therapies, mode of detection, and comorbidities were possible to investigate OS, BCS, as well as recurrence risk of patients undergoing BCT + RT, MT + RT, or MT.Women aged 50-74 years at diagnosis of early-stage invasive breast cancer (I-IIIa) between 2001 and 2005 at the German population-based case-control study (MARIE study) were recruited and followed prospectively as a case cohort until 2015. Kaplan-Meier estimates and stepwise adjusted multivariable Cox models were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI).The 2762 patients included were followed up for a median of 11.9 years (95% CI 11.8-12.0). 74.2% of patients underwent BCT + RT; 10.3% MT + RT and 15.6% MT alone. Compared to patients treated with MT alone, patients treated with BCT + RT showed non-statistically significant improved OS (HR 0.79, 95% CI 0.61-1.02), BCS (HR 0.79, 95% CI 0.55-1.12), and no difference in recurrence risks (HR 1.01, 95% CI 0.74-1.37). For patients treated with MT + RT, there were no differences in OS (HR 1.06, 95% CI 0.75-1.50), BCS (HR 1.17, 95% CI 0.75-1.82), or recurrence risk (HR 1.33, 95% CI 0.89-1.97).Among patients with early-stage breast cancer, clinical outcomes more than 10 years after diagnosis did not differ between the primary treatment options BCT + RT, MT + RT versus MT alone after full adjustment.
000136819 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136819 588__ $$aDataset connected to CrossRef, PubMed,
000136819 7001_ $$0P:(DE-He78)3c7f9136fb168ffb766316ea4ca1a58b$$aRudolph, Anja$$b1$$udkfz
000136819 7001_ $$aObi, Nadia$$b2
000136819 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b3$$udkfz
000136819 7001_ $$aFlesch-Janys, Dieter$$b4
000136819 773__ $$0PERI:(DE-600)2004077-5$$a10.1007/s10549-018-4754-6$$gVol. 170, no. 2, p. 381 - 390$$n2$$p381 - 390$$tBreast cancer research and treatment$$v170$$x1573-7217$$y2018
000136819 909CO $$ooai:inrepo02.dkfz.de:136819$$pVDB
000136819 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3c7f9136fb168ffb766316ea4ca1a58b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136819 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136819 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136819 9141_ $$y2018
000136819 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136819 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES TR : 2015
000136819 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136819 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136819 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136819 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136819 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136819 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136819 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136819 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136819 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136819 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136819 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136819 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000136819 980__ $$ajournal
000136819 980__ $$aVDB
000136819 980__ $$aI:(DE-He78)C020-20160331
000136819 980__ $$aUNRESTRICTED